In the last 25 years, antibiotic modulation of the host-pathogen interaction has become the subject of increased investigational activity (20, 23) . The immunomodulating activity of several antimicrobial agents has been investigated in the past (19, 21, 25, 27) . Unfortunately, most of these studies have focused on in vitro effects (10, 14, 15, 37) . In addition, many controversies evolved from the use of nonstandardized techniques to investigate immunomodulating properties (16, 38) . Recently, flow cytometry methods for the assessment of phagocyte function have proven their considerable accuracy and reproducibility (6, 28, 34, 41) .
The reduction of various neutrophil functions during infection has been demonstrated. Neutrophil adherence (44) , chemotaxis (12) , phagocytosis (33) , and the production of reactive oxygen intermediates (ROI) (43) were diminished during the acute inflammatory response. In addition, plasma isolated from patients with septic shock and incubated with normal neutrophils significantly inhibited superoxide anion production (46) .
Cefodizime was demonstrated to enhance various immune parameters, such as phagocytic function, B lymphocyte responsiveness, and delayed hypersensitivity (20, 21) . In addition, the in vitro effects of this drug include an alteration of bacterial virulence factors (23) . In vivo models of experimental infections show that the prophylactic administration of cefodizime increases the survival of some strains of mice after challenge with Toxoplasma gondii or Candida albicans (19, 25) ; its curative effect in infections due to members of the family Enterobacteriaceae is better than what might have been expected from its in vitro MIC determinations relative to that of other expanded-spectrum cephalosporins (1, 22) . This effect is even more marked in immunocompromised animals (19, 25) .
In contrast, ceftriaxone has an inhibitory effect on lymphocyte responses to phytohemagglutinin. This inhibitory effect on lymphocytes could additionally be enhanced by gentamicin. In general, the effect of this cephalosporin on polymorphonuclear leukocyte (PMNL) function includes a neutral effect on or enhancement of chemotaxis and phagocytosis and a suppressive effect on chemoluminescence (24, 29) . However, clinical studies with humans demonstrating the relevance of these in vitro findings have yet to be reported (19) .
In this study, we longitudinally investigated the influence of cefodizime and ceftriaxone on granulocyte function (11) during the treatment of severe infections (8) . Flow cytometry was used to determine phagocytic capacity and intracellular reactive oxygen production following the phagocytosis of Escherichia coli by granulocytes in the heparinized whole blood of 30 patients with severe infections and in that of a group of healthy controls.
MATERIALS AND METHODS
Patients. The study took place at the Infectious Diseases Unit of the University Hospital of Vienna, Vienna, Austria. A total of 30 randomized patients were enrolled in the study. Twenty-seven age-and sex-matched healthy subjects without infections served as controls. Patients were included in the study if they had symptoms and signs consistent with bacterial infection of the lower respiratory tract, the urinary tract, or bloodstream. Fever (Ͼ38.3ЊC, rectally), tachycardia (Ͼ90 beats per min), and tachypnea (Ͼ20 respirations per min while breathing spontaneously) were additional requirements for inclusion.
After blood, urine, and sputum cultures were obtained, 15 patients were treated with 50 mg of cefodizime per kg of body weight once daily and 15 patients were treated with 50 mg of ceftriaxone per kg once daily (maximal dose, 4 g per day). This dose was necessary because of the severity of the infections and had been well tolerated in the treatment of previous patients. The duration of the cephalosporin administration was 7 to 14 days. The patients were hospitalized for 14 to 21 days. After discharge, patients were monitored at the outpatient clinic. In all cases, the patients or their relatives gave informed consent.
Blood samples and handling. Blood samples were obtained prior to antimicrobial therapy; 1, 3, and 7 days after the initiation of treatment; and 1, 7, and 14 days after the termination of therapy. Venipuncture was performed by a medically qualified operator using sterile 10-ml Vacutainer tubes containing sodium heparin (Becton Dickinson Vacutainer Systems, Rutherford, N.J.). The samples were kept at room temperature until analysis. All assays were performed within 6 h of obtaining the blood.
Preparation of bacteria and dihydrorhodamine (DHR) 123 solution. Heatkilled E. coli ATCC 25922 was labeled with fluorescein isothiocyanate (FITC) (Sigma Chemicals, Munich, Germany) according to the technique described by Cantineaux et al. (9) . Briefly, a 1-ml volume of 0.1 M carbonate buffer, pH 9.6, containing 5 ϫ 10 6 bacteria per ml and 3 g of FITC was incubated at 37ЊC for 30 min. The fluoresceinated bacteria were washed twice in cold Hanks balanced salt solution (Biochrom KG, Berlin, Germany) and resuspended in 50% pooled human sera to a concentration of 10 8 bacteria per ml. The bacteria were stored at Ϫ20ЊC in aliquots until analysis.
DHR 123 was purchased from Molecular Probes Inc. (Eugene, Oreg.) and dissolved in N,N-dimethylformamide (Sigma Chemicals) at a concentration of 3 g/ml. This concentration was achieved by a modification of the method of Rothe et al. (36) .
Phagocytosis assay. Heparinized whole blood (100 l) was aliquoted to the bottom of a 5-ml tube. Before the bacteria samples were added, they were incubated in an ice-water bath for 15 min in order to cool them to 0ЊC. After that, 10 l of precooled, FITC-labeled E. coli was added and incubated with shaking for 10 min at 37ЊC in a water bath. The controls were left on ice. Next, 100 l of precooled quenching solution (Orpegen, Heidelberg, Germany) was added and all samples were washed twice in phosphate-buffered saline (PBS) (pH 7.4). Then, 2 ml of fluorescence-activated cell sorter lysing solution (Becton Dickinson) was added and incubated for 20 min. The samples were then washed with PBS and resuspended for DNA staining at a final concentration of 50 g/ml in 100 l of PBS containing propidium iodide (PI) and kept on ice until analysis.
ROI production. After identical preincubations, the blood samples were stimulated with 25 l of unlabeled E. coli ATCC 25922 (10 8 cells per ml) at 37ЊC. After a 10-min incubation, 25 l of the DHR solution was added and the samples were incubated for an additional 10 min. At the end of the second incubation, 2 ml of the fluorescence-activated cell sorter lysing solution was added and the samples were incubated for 20 min at room temperature. After that, the samples were washed with PBS and resuspended for DNA staining at a final concentration of 50 g/ml in 100 l of PBS containing PI and kept on ice until analysis.
Flow cytometry. The cells were analyzed within 30 min of the addition of the PI with a standard FACScan flow cytometer (Becton Dickinson, Mountain View, Calif.). For each measurement, 10,000 events were collected. Green fluorescence (FL1) was obtained with a 530-nm band pass filter. Red fluorescence (FL2) was collected with a 575-nm band filter. Fluorescence compensation was done to correct any crossover of FITC, DHR 123, and PI fluorescence. For the analysis of ROI production, the granulocytes were separated by setting a gate on the population. To set the gate, the forward scatter (size) and side scatter (granularity) of the cells were determined and recorded. The granulocyte population of the whole blood sample was then identified and gated as shown in Fig. 1A . Granulocytes are characterized as medium-size cells with high granularity (R1). Lymphocytes (R3) and monocytes (R2) can also be identified. To exclude cell debris and nonphagocytized bacteria, a live gate was set on PI-stained leukocytes in FL2 during acquisition (Fig. 1B) . The background scatter was thereby reduced. For the analysis of ROI production, the shift to the right in FL1 (green) was determined ( Fig. 1E and F) . The amount of cleaved substrate was estimated from the mean fluorescence by the statistical option of the FACScan software.
Similarly, the amount of phagocytized bacteria was assessed from the mean fluorescence ( Fig. 1C and D) . The mean fluorescence channels of both assays were compared with those of an unstimulated control (Fig. 1E ) and a 0ЊC control (Fig. 1C) . Daily alignment and calibration of the instrument were done with fluorescence beads (Calibrite; Becton Dickinson). The beads were put into the same histogram channel every day.
Statistical analysis. Differences between the groups were calculated by the Mann-Whitney U test. The ROI production levels and phagocytic capacities of the PMNLs of the patients during the follow-up period were compared by the Wilcoxon rank sum test for dependent samples. Spearman correlation was used. All the analyses were two-sided, and differences with P values of less than 0.05 were considered significant.
RESULTS
Clinical findings. Clinical data on the patients are displayed in Table 1 . Fifteen patients (nine female and six male) ranging in age from 14 to 63 years (median, 30) were treated with ceftriaxone. Four patients had septicemia due to E. coli, Salmonella typhi, Morganella morganii, or Neisseria meningitidis (one each), seven had lobar pneumonia, and four had pyelonephritis due to E. coli. Fifteen patients, nine male and six female ranging in age from 15 to 75 years (median, 36), were treated with cefodizime. Five patients had septicemia due to E. coli (n ϭ 2), streptococci (n ϭ 2), or Hafnia alvei (n ϭ 1), five had lobar pneumonia, and five had pyelonephritis. No differences existed between the groups with regard to age, sex, and disease severity (Table 1 ). In addition, no significant differences between leukocyte counts and between percentages of neutrophils were present (Table 2) .
ROI generation by the PMNLs. Prior to therapy, ROI production in both groups was significantly reduced after ex vivo stimulation of whole blood-derived PMNLs by comparison with that of the healthy controls. After therapy was initiated, ROI production increased and reached normal values for the cefodizime-treated patients after 3 days and for the ceftriaxone group after 7 days ( Fig. 2A and B) (P Ͻ 0.05). In some patients from both groups, the generation of ROI exceeded normal values during follow-up. After the discontinuation of the therapy, PMNL reactive oxygen production was not significantly different among patients of both groups and the controls.
Ex vivo phagocytosis of FITC-labeled E. coli. Figure 3A and B compares the phagocytic capacities of the PMNLs of patients treated with cefodizime and ceftriaxone and with that of the normal controls. Prior to therapy, phagocytosis was decreased in both treatment groups by comparison with that in the healthy controls. In the ceftriaxone-treated patients, phagocytic capacity increased significantly after the start of treatment and normalized on day 7 (Fig. 3A) . After that, no alterations in phagocyte function were seen with these patients (Fig. 3B) . However, in a manner similar to that for ROI production, the phagocytic capacity of the cefodizime-treated patients normalized on day 3 of therapy (P Ͻ 0.05) (Fig. 3A) . After the termination of the treatment, the phagocytic capacity of the PMNLs of the cefodizime-treated patients exceeded the normal range (P Ͻ 0.05) (Fig. 3B) . However, 7 and 14 days 
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Prior to therapy, phagocytic capacity was correlated with ROI production by the PMNLs (r ϭ 0.673 and P Ͻ 0.005). After therapy, no correlation between ROI production and phagocytosis was observed.
DISCUSSION
It has been recognized that phagocytes and their mediators play a crucial role in generating, maintaining, and even worsening the clinical aspects of infectious diseases (11, 17, 45) . Impairment of granulocyte function results in an impaired host defense against invading microorganisms (8, 29) . During infection, a reduction of various granulocyte functions has been demonstrated (12, 33, 43, 44, 46) , whereas an increased ROI production was observed in patients with acute pancreatitis (39) . Alteration of the nonspecific host defense by antibiotics has received increasing interest in the past few years (8) . A new aspect of the study of drug-pathogen-host immunity interactions is the increasing number of immunocompromised individuals for whom even a marginal influence on the host response may have a significant effect on the clinical outcome. The literature on this interaction is still limited and often contradictory because of inaccurate investigational methods (8, 30) . The assessment of phagocytic activity has been performed by a variety of methods, including luminol-amplified chemoluminescence, the nitroblue tetrazolium test, measurement of 14 CO 2 release and of glucose-1-
14
C generated by a hexose monophosphate shunt, and various chemotaxis assays (8, 17, 18, 20, 23, 30) .
By using carefully standardized flow cytometry methods, we measured the phagocytic capacity of and generation of ROI by PMNLs under conditions that minimally disturb the normal microenvironment of these cells (4, 7). It has been demonstrated that isolation from whole blood can alter the expression of cell surface antigens and leukocyte functional behavior as well (2, 3, 5) . In contrast to the practice in previous studies, we did not separate blood leukocytes from their normal microenvironment before incubating them with bacteria (13, 32, 40) . Even so, because anticoagulation with heparin and temperature alterations were required for the experiments, the conditions were not entirely physiologic. However, it is unlikely that the addition of heparin and fluctuations in temperature preferentially influence the phagocytic and ROI-producing capacity of cefodizime-exposed PMNLs as opposed to that of ceftriaxone-exposed leukocytes.
It has been demonstrated that cefodizime in concentrations of up to 100 mg/liter does not directly potentiate an oxidative burst or chemotaxis of PMNLs. Consequently, it has been suggested that cefodizime cooperates with the oxygen-independent bactericidal mechanisms of human neutrophils (19, 21) . We also assessed the effects of ceftriaxone and cefodizime in vitro on the whole blood PMNLs of healthy subjects. No alterations at physiological concentrations of these drugs were recorded by flow cytometry (data not shown). In addition, we studied the effects of cefodizime and ceftriaxone on PMNL function ex vivo in healthy subjects. Blood samples were obtained prior to administration and at 6, 12, 24, and 48 h after the infusion. Regardless of the sampling time, no alteration of PMNL function was observed in these subjects (data not shown). We conclude that while these in vitro findings and ex A stimulatory effect of cefodizime on cytokine production by epithelial cells has been described elsewhere (31) . In this study, cefodizime (by comparison with ceftriaxone) induced a significant, dose-dependent increase in granulocyte-macrophage colony-stimulating factor. No additive effect of cefodizime with tumor necrosis factor was observed in this model. In accordance with our findings, this is of particular interest since granulocyte-macrophage colony-stimulating factor production is an important immunological step for granulocyte recruitment and cell priming during host defense (35) . In addition, extrinsic factors have been demonstrated to suppress PMNL function in patients with septicemia (46) . Thus, a granulocytemacrophage colony-stimulating factor-mediated reversal of impaired granulocyte function during treatment with cefodizime could have contributed to the more rapid normalization of phagocytic and respiratory burst activity and to the enhancement of phagocytic capacity on day 14 ( Fig. 3B) (26) . This is in accordance with findings with patients undergoing hemodialysis, for whom cefodizime stimulated depressed PMNL function even after discontinuation of antimicrobial therapy (42) . The side chain specific to cefodizime is postulated to be the likely determinant of the drug's activity on host defense functions (42) . However, the entire mechanism of action remains unclear.
In general, the effect of cephalosporins on PMNL function includes a neutral effect on or enhancement of chemotaxis and phagocytosis and a suppressive effect on chemoluminescence (24, 29) . In a study assessing the influence of ceftriaxone on natural host defense mechanisms, no change in any phagocyte function (chemotaxis, phagocytosis, phagocytosis-dependent metabolic activation, and microbicidal activity) was observed (18) . We observed a more rapid normalization of phagocytic and ROI-producing capacity in PMNLs of patients with severe infections treated with cefodizime than in ceftriaxone-treated patients (day 3 versus day 7 after the start of treatment, respectively). However, because of the study design (assessment of PMNL function on days 0, 1, 3, 7, 14, 21, and 28 after the initiation of therapy), it is possible that the difference between cefodizime and ceftriaxone disappears earlier than day 7. In addition, the recovery of PMNL phagocytic and respiratory burst activity may be only indirectly due to the drug. The treatment of the underlying bacterial infection might per se improve PMNL function because of changes in the pattern of the host cytokines during treatment or the reduction of bacterium-produced inhibitors.
The present findings demonstrate a dynamic alteration in the activity of PMNLs during severe infections and the subsequent convalescence (47) . Cefodizime-treated patients exhibited a more rapid restoration of depressed PMNL reactive oxygen production and phagocytic capacity by comparison with ceftriaxone-treated patients. The clinical evaluation of the patients is part of a larger clinical comparative study which is currently being performed at our institution. In the immunocompromised host, this enhancement of reactive oxygen production and neutrophil phagocytic capacity may be of clinical significance. VOL. 39, 1995 CEFODIZIME AND CEFTRIAXONE AFFECT PHAGOCYTIC FUNCTION 675
